The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Adverum Biotechnologies, Inc. Common Stock 00773U108   7,166,463 506,822 SH   OTR   0 506,822 0
Aligos Therapeutics, Inc. Common Stock 01626L105   2,273,973 2,320,381 SH   OTR   0 2,320,381 0
CRISPR Therapeutics AG Common Stock H17182108   33,981,713 498,558 SH   OTR   0 498,558 0
Gritstone Oncology, Inc. Common Stock 39868T105   9,152,156 3,561,150 SH   OTR   0 3,561,150 0
Passage Bio, Inc. Common Stock 702712100   6,695,688 4,959,769 SH   OTR   0 4,959,769 0
Repare Therapeutics, Inc. Common Stock 760273102   12,465,754 2,646,657 SH   OTR   0 2,646,657 0
Skye Bioscience, Inc. Common Stock 83086J200   31,400,459 2,007,702 SH   OTR   0 2,007,702 0